Federal Circuit Rejects Claim Construction That Improperly Narrowed the Claim
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
CISCO SYSTEMS, INC. v. TQ DELTA, LLC
Before Newman, Linn, and Wallach. Appeal from Patent Trial and Appeal Board.
Summary: It is improper to read limitations from a preferred embodiment described in the specification into claims without any clear indication that the patentee intended the claims to be limited.
Cisco Systems, Inc. (“Cisco”) and ARRIS Group, Inc. (“Arris”) sought inter partes review of TQ Delta’s patent directed to a method to manage the power of a transceiver in sleep mode and to wake up the transceiver from sleep mode. The Board construed the term “synchronization signal” to mean “a signal allowing synchronization between the clock of the transmitter of the signal and the clock of the receiver of the signal.” Using this construction, the Board found that the claims were not unpatentable over the prior art.
The Federal Circuit reversed, holding that the Board construed the terms too narrowly to the advantageous clock-based embodiment, excluding “frame synchronization.” The Federal Circuit stated that the patent’s claims and specifications teach that “synchronization signal” is not limited to describing what the signal must synchronize or a particular type of synchronization (i.e., clock-based). The Federal Circuit determined that “synchronization signal” simply means “used to establish or maintain a timing relationship between transceivers between the transmitter of the signal and the receiver of the signal,” meaning synchronization signal includes frame synchronization. Accordingly, The Federal Circuit vacated the Board’s decision and remanded for the Board to consider Appellants’ unpatentability challenges under the proper claim construction.
Editor: Paul Stewart
Written by: Bita Kianian & Kendall Loebbaka
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…